InVera Medical Reports 90% Vein Closure Success Rate in 12-Month Chronic Venous Disease Trial

Key Takeaways

• InVera Infusion Device achieved 90% vein closure rates in 12-month pilot trial for chronic venous disease treatment
• Patients experienced statistically significant quality of life improvements with excellent safety profile
• Results presented at International Charing Cross Symposium position device as promising minimally-invasive CVD treatment option

---

GALWAY, Ireland - InVera Medical announced positive 12-month results from its pilot clinical study of the InVera Infusion Device for treating Chronic Venous Disease (CVD), showing a 90% vein closure rate and significant patient quality of life improvements.

Dr. Lowell Kabnick, Past President of the American Venous Forum and head of InVera’s Medical Advisory Board, presented the findings at the International Charing Cross Symposium on April 21, 2026.

Strong Efficacy and Safety Profile

The pilot trial demonstrated the device’s effectiveness in treating CVD, a condition affecting millions worldwide that causes leg pain, swelling, and potentially serious complications if left untreated. The 90% vein closure rate represents a significant achievement for minimally-invasive vascular treatments.

“These results validate our approach to chronic venous disease treatment,” said Dr. Kabnick during the presentation. The study also reported excellent safety outcomes, with no major adverse events attributed to the device.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Treatment Landscape

Chronic venous disease affects approximately 25 million Americans, with traditional treatments ranging from compression therapy to surgical interventions. The InVera Infusion Device offers a minimally-invasive alternative that could reduce recovery times and improve patient outcomes.

The medical device company, focused on advancing minimally-invasive technologies for vascular conditions, positions this technology as a potential game-changer in the CVD treatment market, which is expected to grow significantly as populations age.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps and Regulatory Path

Following these promising pilot results, InVera Medical is expected to pursue larger-scale clinical trials to support regulatory submissions. The company has not yet announced specific timelines for broader clinical development or commercial availability.

The positive 12-month data provides a strong foundation for advancing the InVera Infusion Device through the regulatory approval process, potentially offering patients a new treatment option for this common vascular condition.

---

Frequently Asked Questions

What is chronic venous disease and how common is it?

Chronic venous disease is a vascular condition causing leg pain, swelling, and circulation problems. It affects approximately 25 million Americans and can lead to serious complications if untreated.

When will the InVera Infusion Device be available to patients?

The device is currently in clinical trials. InVera Medical has not announced specific timelines for regulatory approval or commercial availability following these 12-month pilot results.

How does the InVera device compare to current CVD treatments?

The device offers a minimally-invasive approach with 90% vein closure rates, potentially providing faster recovery times compared to surgical options while being more effective than conservative treatments like compression therapy.

Related coverage

• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Vabysmo gains EU approval for retinal vein occlusion: what changes next
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial